ArticleLupus science & medicine2025
Burden of herpes zoster among patients with systemic lupus erythematosus in the USA.
Article in Lupus science & medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of the Safety of Recombinant Zoster Vaccine on Patients with Systemic Lupus Erythematosus in a Tertiary Hospital in Saudi Arabia: A Retrospective Single Centre Study.Mediterranean journal of rheumatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs associated with HZ among adults with systemic lupus erythematosus (SLE).
methodsThis retrospective cohort study included insured patients from 2015 to 2022. HZ incidence rates were estimated among patients with SLE, SLE without other immunocompromising conditions (ICC) (SLE only) and no ICC. Adjusted incidence rate ratios (aIRRs) and 95% confidence intervals (CIs) comparing the SLE and SLE only cohorts versus the no ICC cohort were estimated using Poisson regression. All-cause HRU and costs were compared between patients with SLE and HZ (SLE+/HZ+) and propensity score matched patients with SLE without HZ (SLE+/HZ-).
resultsThe incidence rates of HZ in the SLE (n=60 430), SLE only (n=21 206) and no ICC (n=1 000 000) cohorts were 19.72, 14.03 and 5.64 per 1000 patient-years, respectively (aIRR 1.89, 95% CI 1.79 to 2.00, and aIRR 1.54, 95% CI 1.40 to 1.69). Mean all-cause per-patient costs were significantly higher in the SLE+/HZ+ versus SLE+/HZ- cohorts during the first 1 month (n=2126 and n=8504, respectively; cost difference $1349, 95% CI $722 to 1977) and 3 months (n=1968 and n=7872; $1558, 95% CI $108 to 3007).
conclusionsPatients with SLE had a significantly higher incidence of HZ compared with adults without ICC. Patients with SLE who developed HZ incurred significantly higher all-cause costs than those who did not. These data support considering HZ vaccination for patients with SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.